drugset / Trial / NCT00054041

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00054041

Phase 2 Completed 84 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer. Randomized phase II trial to study the effectiveness of vaccine therapy in preventing cervical cancer in patients who have cervical intraepithelial neoplasia

Timeline

Start
2004-06
Primary completion
2007-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject VERPASEP CALTESPEN Vaccine Subcutaneous